New Study Results Published Compare ABRAXANE(R) To Taxotere(R)
 

Abraxis BioScience Inc. (NASDAQ:ABII) announced that final results from an open-label Phase II study evaluating three dose levels of the company's chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) compared to the highest standard dose of Taxotere (docetaxel) Injection Concentrate, in the first-line treatment of patients with metastatic breast cancer were published in the Journal of Clinical Oncology.

More...